Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Accumulated Expenses: 2012-2025

Historic Other Accumulated Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 12 years, with Sep 2025 value amounting to $10.8 million.

  • Arrowhead Pharmaceuticals' Other Accumulated Expenses rose 2402.55% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 2402.55%. This contributed to the annual value of $10.8 million for FY2025, which is 2402.55% up from last year.
  • As of FY2025, Arrowhead Pharmaceuticals' Other Accumulated Expenses stood at $10.8 million, which was up 2,402.55% from $432,000 recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Other Accumulated Expenses registered a high of $10.8 million during FY2025, and its lowest value of $432,000 during FY2024.
  • For the 3-year period, Arrowhead Pharmaceuticals' Other Accumulated Expenses averaged around $3.9 million, with its median value being $435,000 (2023).
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Other Accumulated Expenses declined by 0.69% in 2024 and then skyrocketed by 2,402.55% in 2025.
  • Arrowhead Pharmaceuticals' Other Accumulated Expenses (Yearly) stood at $435,000 in 2023, then dropped by 0.69% to $432,000 in 2024, then surged by 2,402.55% to $10.8 million in 2025.